SIENA, SALVATORE
SIENA, SALVATORE
Dipartimento di Oncologia ed Emato-Oncologia
A phase II/III randomized clinical trial of CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative chemotherapy versus immediate resection in patIents with resecTable BiliarY Tract Cancers (BTC) at high risk for recurrence: PURITY study
2024 M. Niger, F. Nichetti, L. Fornaro, C. Pircher, F. Morano, F. Palermo, L. Rimassa, T. Pressiani, R. Berardi, A.C. Gardini, E. Sperti, L. Salvatore, D. Melisi, F. Bergamo, S. Siena, S. Mosconi, R. Longarini, G. Arcangeli, S. Corallo, L. Delliponti, S. Tamberi, E. Fea, G. Brandi, I.G. Rapposelli, M. Salati, P. Baili, R. Miceli, S. Ljevar, I. Cavallo, E. Sottotetti, A. Martinetti, M.D.D. Busset, C. Sposito, M. Di Bartolomeo, F. Pietrantonio, F. de Braud, V. Mazzaferro
Brief Report: Updated Efficacy and Safety Data From an Integrated Analysis of Entrectinib in Locally Advanced/Metastatic ROS1 Fusion-Positive Non-Small-Cell Lung Cancer
2024 Y. Fan, A. Drilon, C. Chiu, H.H.F. Loong, S. Siena, M. Krzakowski, R. Dziadziuszko, H. Zeuner, C. Xue, M.G. Krebs
Curative immune checkpoint inhibitors therapy in patients with mismatch repair-deficient locally advanced rectal cancer: a real-world observational study
2024 F. Tosi, L. Salvatore, E. Tamburini, S. Artale, S. Lonardi, S. Marchetti, A. Pastorino, F. Pietrantonio, A. Puccini, F.L. Rojas-Llimpe, B. Vincenzi, S. Mariano, F. Negri, K. Bencardino, C. Pinto, C. Aschele, S. Siena
Trastuzumab deruxtecan in patients with solid tumours harbouring specific activating HER2 mutations (DESTINY-PanTumor01): an international, phase 2 study
2024 B.T. Li, F. Meric-Bernstam, A. Bardia, Y. Naito, S. Siena, P. Aftimos, I. Anderson, G. Curigliano, M. de Miguel, M. Kalra, D. Oh, J.O. Park, S. Postel-Vinay, S.Y. Rha, T. Satoh, I. Spanggaard, F. Michelini, A. Smith, K.K. Machado, C. Saura
Efficacy of Trastuzumab Deruxtecan in HER2-Expressing Solid Tumors by Enrollment HER2 IHC Status: Post Hoc Analysis of DESTINY-PanTumor02
2024 A. Oaknin, J. Lee, V. Makker, D. Oh, S. Banerjee, A. González-Martín, K.H. Jung, I. Ługowska, L. Manso, A. Manzano, B. Melichar, S. Siena, D. Stroyakovskiy, A. Fielding, S. Puvvada, A. Smith, F. Meric-Bernstam
Characteristics and Survival Outcomes of Patients With Metastatic RET Fusion-Positive Solid Tumors Receiving Non-RET Inhibitor Standards of Care in a Real-World Setting
2024 A. Hackshaw, O. Fajardo, U. Dafni, H. Gelderblom, P. Garrido, S. Siena, M.H. Taylor, W. Bordogna, C. Nikolaidis
Ongoing Clinical Trials and Future Research Scenarios of Circulating Tumor DNA for the Treatment of Metastatic Colorectal Cancer
2024 L. Roazzi, G. Patelli, K.B. Bencardino, A. Amatu, E. Bonazzina, F. Tosi, B. Amoruso, A. Bombelli, S. Mariano, S. Stabile, C. Porta, S. Siena, A. Sartore-Bianchi
Clinicopathological characterisation of MTAP alterations in gastrointestinal cancers
2024 G. Mauri, G. Patelli, L. Roazzi, E. Valtorta, A. Amatu, G. Marrapese, E. Bonazzina, F. Tosi, K. Bencardino, G. Ciarlo, E. Mariella, S. Marsoni, A. Bardelli, E. Bonoldi, A. Sartore-Bianchi, S. Siena
Tolerance to colibactin correlates with homologous recombination proficiency and resistance to irinotecan in colorectal cancer cells
2024 A. Sogari, E. Rovera, G. Grasso, E. Mariella, N.M. Reilly, S. Lamba, G. Mauri, E. Durinikova, P.P. Vitiello, A. Lorenzato, M. Avolio, E. Piumatti, E. Bonoldi, M.C. Aquilano, S. Arena, A. Sartore-Bianchi, S. Siena, L. Trusolino, M. Donalisio, M. Russo, F. Di Nicolantonio, D. Lembo, A. Bardelli
Trastuzumab deruxtecan in patients with HER2-positive advanced colorectal cancer (DESTINY-CRC02): primary results from a multicentre, randomised, phase 2 trial
2024 K. Raghav, S. Siena, A. Takashima, T. Kato, M. Van den Eynde, F. Pietrantonio, Y. Komatsu, H. Kawakami, M. Peeters, T. Andre, S. Lonardi, K. Yamaguchi, J. Tie, C.G. Castro, H. Hsu, J.H. Strickler, T. Kim, Y. Cha, D. Barrios, Q. Yan, T. Kamio, K. Kobayashi, A. Boran, M. Koga, J.D. Allard, T. Yoshino
Anti-EGFR Rechallenge in Patients With Refractory ctDNA RAS/BRAF wt Metastatic Colorectal Cancer: A Nonrandomized Controlled Trial
2024 D. Ciardiello, E. Martinelli, T. Troiani, G. Mauri, D. Rossini, G. Martini, S. Napolitano, V. Famiglietti, S. Del Tufo, G. Masi, D. Santini, A. Avallone, F. Pietrantonio, S. Lonardi, M. Di Maio, M.G. Zampino, N. Fazio, A. Bardelli, S. Siena, C. Cremolini, A. Sartore-Bianchi, F. Ciardiello
Prediction of homologous recombination deficiency identifies colorectal tumors sensitive to PARP inhibition
2024 G. Corti, K. Buzo, E. Berrino, M. Miotto, M.C. Aquilano, M. Lentini, S.E. Bellomo, A. Lorenzato, A. Bartolini, G. Mauri, L. Lazzari, M. Russo, F. Di Nicolantonio, S. Siena, S. Marsoni, C. Marchiò, A. Bardelli, S. Arena
A Comparative Study of Methyl-BEAMing and Droplet Digital PCR for MGMT Gene Promoter Hypermethylation Detection
2024 M. Macagno, V. Pessei, N. Congiusta, L. Lazzari, S.E. Bellomo, F. Idrees, A. Cavaliere, F. Pietrantonio, A. Raimondi, E. Gusmaroli, M.G. Zampino, L. Gervaso, D. Ciardiello, G. Mondello, A. Santoro, N. Personeni, E. Bonoldi, M.C. Aquilano, E. Valtorta, S. Siena, A. Sartore-Bianchi, A. Amatu, E.F. Bonazzina, K.B. Bencardino, G. Serini, S. Marsoni, L. Barault, F. Di Nicolantonio, F. Maione
Early-onset cancers: Biological bases and clinical implications
2024 G. Mauri, G. Patelli, A. Sartore-Bianchi, S. Abrignani, B. Bodega, S. Marsoni, V. Costanzo, A. Bachi, S. Siena, A. Bardelli
The role of anti-EGFR rechallenge in metastatic colorectal cancer, from available data to future developments: A systematic review
2024 D. Ciardiello, G. Mauri, A. Sartore-Bianchi, S. Siena, M.G. Zampino, N. Fazio, A. Cervantes
Young-onset colorectal cancer: treatment-related nausea, vomiting and diarrhoea
2023 G. Mauri, M. Pedrani, S. Ghezzi, K. Bencardino, S. Mariano, E. Bonazzina, F. Serra, P. Pedrazzoli, R. Caccialanza, G.M. Cavestro, S. Siena, S. Artale, A. Sartore-Bianchi
What to do after immune-checkpoint inhibitors failure in advanced non-small cell lung cancer: an expert opinion and review
2023 A.G. Agostara, L. Roazzi, F. Villa, R. Romano’, D. Piscazzi, F. Martinelli, G. Ciarlo, S. Oresti, F. Travaglini, A. Marando, A. Sartore-Bianchi, L. Giannetta, G. Cerea, S. Siena, E.G. Pizzutilo, D. Signorelli
Trastuzumab deruxtecan in patients in the USA and Europe with HER2-positive advanced gastric or gastroesophageal junction cancer with disease progression on or after a trastuzumab-containing regimen (DESTINY-Gastric02): primary and updated analyses from a single-arm, phase 2 study
2023 E. Van Cutsem, M. di Bartolomeo, E. Smyth, I. Chau, H. Park, S. Siena, S. Lonardi, Z.A. Wainberg, J. Ajani, J. Chao, Y. Janjigian, A. Qin, J. Singh, F. Barlaskar, Y. Kawaguchi, G. Ku
Immune Checkpoint Inhibitors and the Exposome: Host-Extrinsic Factors Determine Response, Survival, and Toxicity
2023 E.G. Pizzutilo, R. Romanò, L. Roazzi, A.G. Agostara, S. Oresti, A. Zeppellini, L. Giannetta, G. Cerea, D. Signorelli, S. Siena, A. SARTORE BIANCHI
Repotrectinib Overcomes F2004V Resistance Mutation in ROS1-Rearranged NSCLC: A Case Report
2023 E.G. Pizzutilo, A.G. Agostara, L. Roazzi, R. Romanò, V. Motta, C. Lauricella, G. Marrapese, G. Cerea, D. Signorelli, S. Marco Veronese, L. Giuseppina Giannetta, A. Sartore-Bianchi, S. Siena